VitriVax closed an $87 million Series C to take its experimental single-dose Lyme disease vaccine into its first human trial, the Boulder, Colorado, company announced on November 18.
VitriVax aims to combine doses that would otherwise require separate vaccination visits into one injection. Its ALTA platform packages vaccine ingredients in protective sugar glass particles, then adds coatings that control their release over time, according to the company’s technology description. The approach also aims to reduce refrigeration needs.
F-Prime, NEA, RA Capital Management and Sanofi Ventures co-led the financing, with Eli Lilly and other existing investors participating. The round is about five times the $17.25 million Series B VitriVax announced in October 2025.
The new capital will also support a pipeline of vaccines owned by VitriVax. Its earlier partnership work includes research with Serum Institute of India, announced in April 2025, to investigate whether an existing three-dose rabies vaccine could be reformulated for one injection.
No human Lyme vaccine is currently available, according to the CDC. The agency’s April 2026 update notes that the previous US product, LYMERix, was discontinued in 2002 because of insufficient consumer demand.
Pfizer and Valneva are further along with a competing candidate that used four doses in its Phase 3 trial. On August 14, they announced that European regulators had accepted its application for review.